Abstract
Cancer is the leading cause of death in Puerto Rico (PR). Hurricane Maria (HM) and its aftermath lead to widespread devastation in the island, including the collapse of the healthcare system. Medically fragile populations, such as cancer survivors, were significantly affected. The goal of this study was to assess the impact of HM on barriers to care, emotional distress, and inflammatory biomarkers among cancer survivors in PR. This exploratory longitudinal study was conducted in health care facilities and community support groups from PR. Cancer survivors (n=50) and non-cancer participants (n=50) completed psychosocial questionnaires and provided blood samples that were used to assess inflammatory cytokines levels. Data were analyzed through descriptive, frequencies, correlational, and linear regression analyses. Cancer survivors that were affected by HM reported increased barriers in accessing medical care, which were directly associated with anxiety, perceived stress, and post-traumatic symptomatology. Moreover, being a cancer survivor, along with closeness in time from HM predicted more barriers to receiving health care. Several inflammatory cytokines, such as CD31, BDNF, TFF3, Serpin E-1, Vitamin D BP, VCAM-1, Osteopontin, Chitinase 3 like 1, MMP-9 and MIF were significantly upregulated in cancer survivors while BDNF, MMP9 and Osteopontin had significant positive correlations with barriers to care. HM significantly impacted Puerto Ricans psychosocial well-being. Cancer survivors had significant barriers to care and showed increased serum inflammatory cytokines, but didn’t show differences in anxiety, stress and post-traumatic symptoms compared to non-cancer participants.
Competing Interest Statement
HJ serves as a consultant to RedHill BioPharma and Janssen Scientific Affairs. Other authors declare no potential conflicts of interest.
Clinical Trial
n/a
Funding Statement
This work was supported by grants from the NIH NCI U54CA163071 and U54CA163068, NIH NIMHD R21MD013674 and G12MD007579, NIH NIGMS P20GM103475 and NIH NIMHD/NIAID U54MD007587. CBC-E was supported by grants from the NIH NIGMS R25GM082406 and NIH NCI F31CA232622.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Footnotes
Funding: This work was supported by grants from the NIH NCI U54CA163071 and U54CA163068, NIH NIMHD R21MD013674 and G12MD007579, NIH NIGMS P20GM103475 and NIH NIMHD/NIAID U54MD007587. CBC-E was supported by grants from the NIH NIGMS R25GM082406 and NIH NCI F31CA232622.
Conflict of Interest: HJ serves as a consultant to RedHill BioPharma and Janssen Scientific Affairs. Other authors declare no potential conflicts of interest.
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
